• Efficacy of Itraconazole in Preconceptional Prevention of Recurrent Vulvovaginal Candidiasis

Efficacy of Itraconazole in Preconceptional Prevention of Recurrent Vulvovaginal Candidiasis

PERINATOLOGIYA I PEDIATRIYA. 2017.2(70):74-78; doi 10.15574/PP.2017.70.74

Ogorodnyk A. A., Davydova Iu. V.
SI «Institute of Pediatrics, Obstetrics and Gynecology of NAMS of Ukraine», Kyiv

Objective — to determine the efficacy of Funit (Itraconazole) during the preconceptional preparation of women with recurrent vulvovaginal candidiasis.

Materials and methods. The main group consisted of 36 women with recurrent vulvovaginal candidiasis, sensitive to Intraconazole, who were administrated Funit (Itraconazole) during the preconceptional period. The comparison group comprised 34 women, treated symptomatically with the local antimycotic (imidazole derivative). Groups are matched by age, social status, and living conditions. The average age was 25±4.7 years. The vulvovaginal candidiasis was diagnosed by clinical and medical history data, microscopic and culture:based microflora studies that were performed prior to therapy and in 3 and 6 months after its completion. The exclusion criterion was the sexually transmitted infections, such as trichomoniasis, gonorrhea, and chlamydiosis.

Results. Funit is considered to be a highly effective and safety medication for the treatment of recurrent vulvovaginal candidiasis during the preconceptional period. The duration of the effect during the control follow:up study in 3 months on completing of therapy made up 95%. The drug is well tolerated and does not cause adverse reactions in women.

Conclusions. Due to high anti:relapse action, Funit can be recommended as a part of complex preconceptional preparation.

Key words: preconceptional preparation, recurrent vulvovaginal candidiasis, Intraconaszole.

References
1. Savini V, Catavitello C, Bianco A et al. (2009). Azole resistant Candida glabrata vulvovaginitis treated with boric acid. Eur J Obstet Gynecol Reprod Biol. 147(1): 112. https://doi.org/10.1016/j.ejogrb.2009.06.020; PMid:19619928

2. Marchaim D, Lemanek L, Bheemreddy S et al. (2012). Floconazole-resistant Candida albicans vulvovaginitis. Obstet Gynecol. 120(6): 1407—1414. https://doi.org/10.1097/AOG.0b013e31827307b2; PMid:23168767

3. Gelber S, Nyirjesy P. (2005). Update on vulvovaginal candidiasis. The Female Patient. 30: 36-46.

4. Pappas PG, Rex JH, Sobel JD et al. (2004). Guidelines for the treatment of candidiasis. Clin Infect Dis. 38(2): 161—189. Epub 2003 Dec. 19. https://doi.org/10.1086/380796; PMid:14699449

5. Sobel JD, Wiesenfeld HC, Martens M et al. (2004). Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis. N Engl J Med. 351(9): 876—883. https://doi.org/10.1056/NEJMoa033114; PMid:15329425

6. Norgaard M, Pedersen L, Gislum M et al. (2008). Maternal use of fluconazole and risk of congenital malformations: a Danish population-based cohort study. J Antimicrob Chemother. 62(1): 172—176. Epub. 2008 Apr. 9. https://doi.org/10.1093/jac/dkn157; PMid:18400803

7. Mendling W, Brasch J. (2012). Guideline vulvovaginal candidosis (2010) of the German Society for Gynecology and Obstetrics, the Working Group for Infections and Infectimmunology in Gynecology and Obstetrics, the German Society of Dermatology, the Board of German Dermatologists and the German Speaking Mycological Society. Mycoses. 55(3): 1—13. https://doi.org/10.1111/j.1439-0507.2012.02185.x; PMid:22519657

8. Jankovice S, Bojovice D, Vukadinovice D et al. (2010). Risk factors for recurrent vulvovaginal candidiasis. Vojnosanit Pregl. 67(10): 819—824. https://doi.org/10.2298/VSP1010819J

9. Xu J, Sobel JD. (2003). Antibiotic-associated vulvovaginal Candidiasis. Curr Infect Dis Rep. 5: 481—487. https://doi.org/10.1007/s11908-003-0091-x; PMid:14642189

Содержание журнала Full text of article